QLS1209 / Qilu Pharma - LARVOL DELTA

QLS1209, A highly potent and selective PKMYT1 inhibitor demonstrates activity in tumors with CCNE1Amp and/ or FBXW7LoF mutations (AACR 2025) - "QLS1209 was well tolerated and demonstrated anti-tumor activity in CCNE1Amp HCC1569 and OVCAR3 xenograft models in vivo, it also showed enhanced efficacy when combined with Gemcitabine. IND enabling studies are currently underway and are expected to be completed by the end of 2024. Collectively, these findings highlight the promising potential of QLS1209 as a therapeutic strategy, either as monotherapy or in combination with other anti-cancer therapies, for a variety of cancer types characterized by CCNE1Amp and/ or FBXW7LoF mutations."

Colorectal Cancer • Gynecologic Cancers • Oncology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • CCNE1 • CDK1 • FBXW7 • PKMYT1